NCT06337071View on ClinicalTrials.gov

A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2025

Conditions
Meningococcal Meningitis
Interventions
BIOLOGICAL

ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.

BIOLOGICAL

ACYW135 Meningococcal Polysaccharide Vaccine

ACYW135 Meningococcal Polysaccharide Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135.

Trial Locations (1)

650022

Yunnan Center For Disease Control and Prevention, Kunming

All Listed Sponsors
lead

Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

INDUSTRY